Licence extension for Januvia

Januvia (sitagliptin) is now licensed for first-line treatment of type II diabetes when metformin is contraindicated or not tolerated. The recommended dose is 100mg once daily.

View Januvia drug record

Further information: Merck

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Januvia no longer contraindicated in renal impairment

Januvia no longer contraindicated in renal impairment

Januvia (sitagliptin) can now be used at a lower dose...

New DPP4 inhibitor launched

New DPP4 inhibitor launched

Bristol Myers-Squibb and AstraZeneca have launched...

Januvia licence extension

The licence for Januvia (sitagliptin) has been extended...

SMC product assessment decisions

The Scottish Medicines Consortium (SMC) has announced...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases